Instrument Inactif

Autres langues CVTX

Actions

US1266671049

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CV THERAPEUTICS : CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer	12/03/09
CV THERAPEUTICS : Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer	27/02/09
CV THERAPEUTICS : CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal	20/02/09
CV THERAPEUTICS : Statement on Unsolicited Proposal From Astellas	28/01/09
CV THERAPEUTICS : FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c	06/11/08
CV THERAPEUTICS : to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008	23/10/08
CV THERAPEUTICS : Announces License Agreement for Ranexa(R) in Europe With Menarini Group	12/09/08
CV THERAPEUTICS : Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases	02/09/08
CV THERAPEUTICS : Reports Option Grants Under Nasdaq Marketplace Rule 4350	27/08/08
CV THERAPEUTICS : Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome	19/08/08
CV THERAPEUTICS : Receives European Approval for the Brand Name Ranexa(R)	14/08/08
CV THERAPEUTICS : Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award	14/08/08
CV THERAPEUTICS : CVT Announces That FDA Continues to Review Ranexa(R) Applications	28/07/08
CV THERAPEUTICS : to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008	22/07/08
CV THERAPEUTICS : Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina	10/07/08
CV THERAPEUTICS : Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)	24/06/08
CV THERAPEUTICS : Reports Option Grants Under Nasdaq Marketplace Rule 4350	28/05/08
Cv Therapeutics : European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina	24/04/08
Cv Therapeutics : CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008	14/04/08
Cv Therapeutics : CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results	26/02/08

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues CVTX

Actions

US1266671049

Autres langues

Filtres